An insight on regulations governing orphan diseases and drugs

Research Journal of Pharmaceutical, Biological and Chemical Sciences

Volumn 2, Issue 3, 2011, Pages 373-384

  Kataria, Mahesh Kumar ^a   Garg, Meena ^a   Anand, Vikas ^a   Bilandi, Ajay ^a   Kukkar, Vipin ^a   Bhandari, Anil ^b  

^a Institute of Pharmaceutical Sciences and Drug Research   (India)

^b Jodhpur National University   (India)

Author keywords

Neglected disease; Orphan disease; Orphan drug; Orphan drug act; Rare disease; Regulation

Indexed keywords

AFAMELANOTIDE; BOSENTAN; CARBIDOPA PLUS LEVODOPA; CATUMAXOMAB; EVEROLIMUS; ORPHAN DRUG; ROMIDEPSIN; SUNITINIB; TADALAFIL; TERLIPRESSIN; TOBRAMYCIN; VANDETANIB;

ARTICLE; AUSTRALIA; CLINICAL RESEARCH; DRUG EFFICACY; DRUG INDUSTRY; DRUG LEGISLATION; DRUG RESEARCH; DRUG SAFETY; DRUG STABILITY; EUROPE; GOVERNMENT; HUMAN; JAPAN; ORPHAN DISEASE; PHARMACODYNAMICS; PHYSICAL DISEASE; UNITED STATES;

EID: 79960945867     PISSN: None     EISSN: 09758585     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Drug Facts and Comparisons, Orphan drugs, St. Louis, MO: Facts & Comparisons, A Wolters Kluwar Company 2002; 56 edition, KU-1 - KU-22
2. Aronson JK. Br J Clin Pharmacol 2006; 61(3): 243-245.
3. http://www.fda.gov/orphan/oda.htm
4. http://www.europabio.org
5. http://www.hon.ch/HONselect/RareDiseases/
6. Villarreal MA: Orphan Drug Act: Background and Proposed Legislation in the 107th Congress, CRS Report for Congress 2001
7. Randhawa GK. Ind J Pharmacol 2006; 38 (3): 171-176.
8. Badyal D. Ind J Pharmacol 2006; 38(4): 299-300.
9. Sumanth M, Parasher S. Indian J Pharm Sci 2004; 66: 587-594.
10. http://ec.europa.eu/enterprise/pharmaceuticals/register/orphreg.htm (Accessed on 28.01.2011)
11. Rohde DD. Food & Drug Law Journal 2000; 55: 125-143.
12. The US FDA orphan drug product program, Orphan Drug Product White Paper, Beckloff Associates, Inc, A Cardinal Health Company; 1-4 http://www.cardinalhealth.com/beckloff/documents/pdf/Orphan%20Drug%20Product%20White%20Paper.pdf (Accessed on 10.01.2011)
13. Villa S, Compagni A, Reich MR: Orphan drug legislation: lessons for neglected tropical diseases, International Journal of Health Planning and Management, 2008, DOI: 10.1002/hpm
14. The Orphan Drug Act Implementation and Impact, Office of Inspector General, Department of Health And Human Services, USA
15. http://www.orpha.net/consor/cgi-in/Education_AboutOrphanDrugs.php?lng=EN&stapage=ST_EDUCATION_EDUCATION_ABOUTORPHANDRUGS_USA (Accessed on 10.01.2011)
16. Bigoniya P. The Pharma Review 2010; 83-87
17. FDA grants orphan drug status to RiVax, PBR Regulatory Affair, pharmaceutical-business-review (Available at http://regulatoryaffairs.pharmaceutical-business-review.com/news/fda-grants-orphan-drug-status-to-rivax-soligenix-200111) (Accessed on 24.01.2011)
18. http://www.orpha.net/consor/cgi-bin/Education_AboutOrphanDrugs.php?lng=EN&stapage=ST_EDUCATION_EDUCATION_ABOUTORPHANDRUGS _JAP (Accessed on 25.12.2010)
19. http://www.tga.gov.au/docs/html/tganews/news43/med.htm#orphan (Accessed on 15.12.2010)
20. Australian regulatory guidelines for prescription medicines, Therapeutic Goods Administration, Department of Health & Ageing, Australian Government, 2004
21. http://www.tga.gov.au/docs/html/orphand2.htm (Accessed on 11.12.2010)
22. Orphan drugs and rare diseases at a glance, European Medical Agency, Press office, London 2007
23. http://www.orpha.net/consor/cgi-in/Education_AboutOrphanDrugs.php?lng=ENstapage=ST_EDUCATION_EDUCATION_ABOUTORPHANDRUGS_EUR (Accessed on 25.12.2010)
24. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000029.jsp&murl=menus/regulations/regulations.jsp&mid=WC0b01ac05800240ce (Accessed on 25.12.2010)
25. Pre- authorisation Evaluation of Medicines for Human Use, European Medicines Agency, London 2009. (Available at http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2009/09/WC500003876.pdf) (Accessed on 04.12.2010)
26. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/orphan_search.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d12b (Accessed on 15.12.2010)
27. http://www.orpha.net/consor/cgi-in/Education_AboutOrphanDrugs.php?lng=EN&stapage=ST_EDUCATION_EDUCATION_ABOUTORPHANDRUGS_COMPARISON (Accessed on 02.02.2011)
28. Stolk P, Willemen M, Leufkens HG: Rare essentials? Drugs for rare diseases on the Essential Medicines List, Utrecht Institute for Pharmaceutical Science, The Netherlands, 2005 (available at http://archives.who.int/eml/expcom/expcom14/1other/Rare_diseases_finalMarch1_2005.pdf) (Accessed on 25.12.2010)
29. Kak A. Express Pharma, (Availabe at http://www.expresspharmaonline.com/20080831/research01.shtml) (Accessed on 10.12.2010)
30. Mangathayaru K, Sivakumar A, Chitra K, Sujatha K, Sravan K. Pharmainfo.net Dec 2007; 5 (1). (Available at http://www.pharmainfo.net/reviews/orphan-diseases-indian-perspective) (Accesses on 02.01.2011)